InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

InspireMD Stock Up 2.2 %

Shares of NSPR stock opened at $1.89 on Wednesday. InspireMD has a fifty-two week low of $1.03 and a fifty-two week high of $3.85. The stock has a market cap of $44.23 million, a P/E ratio of -1.75 and a beta of 0.83. The business has a fifty day simple moving average of $2.38 and a 200-day simple moving average of $2.68.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. The business had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.65 million. During the same quarter last year, the business posted ($0.60) earnings per share. On average, sell-side analysts anticipate that InspireMD will post -0.61 earnings per share for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Avestar Capital LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $65,000. Avestar Capital LLC owned about 0.09% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.